Puma Biotechnology

243 articles with Puma Biotechnology

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 5, 2019

  6/5/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 3, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 82,063 shares of Puma common stock to 15 new non-executive employees.

• CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting

  6/4/2019

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago.

• Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting

  6/4/2019

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease, were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago.

• Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting

  6/2/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology 2019 Annual Meeting in Chicago.

• Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference

  5/29/2019

  Puma Biotechnology, Inc. announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m. EDT on Thursday, June 6, at the Jefferies 2019 Global Healthcare Conference.

• 

  Puma's Nerlynx Edges Out Novartis' Tykerb in Breast Cancer Trial

  5/17/2019

  Patients were randomized 1:1 to receive Nerlynx and Xeloda or Tykerb and Xeloda. Co-primary endpoints were progression-free survival and overall survival.

• Puma Biotechnology Reports First Quarter 2019 Financial Results

  5/9/2019

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2019.

• Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019

  5/8/2019

  The conference will be held at Encore at the Wynn in Las Vegas.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 3, 2019

  5/3/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 3, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 49,125 shares of Puma common stock to nine new non-executive employees.

• Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

  4/25/2019

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 9, 2019 following release of its first quarter 2019 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 9, 2019

  4/9/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on April 3, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 45,625 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations

  4/4/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2 mutation.

• Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe

  4/1/2019

  Pierre Fabre will have exclusive commercialization rights for NERLYNX in European countries excluding Russia and Ukraine, along with countries in North Africa and francophone countries of West Africa.

• Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019

  3/28/2019

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2019.

• Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

  3/18/2019

  Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy.

• Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting

  3/18/2019

  Puma Biotechnology, Inc. an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting in Honolulu, Hawaii.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 14, 2019

  3/14/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688 shares of Puma common stock to five new non-executive employees.

• Puma Biotechnology to Present at Cowen’s Annual Health Care Conference

  3/5/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m. EDT on Tuesday, March 12 at the Cowen and Company 39th Annual Health Care Conference.

• Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results

  2/28/2019

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  2/15/2019

  Puma Biotechnology, Inc. announced that on February 14, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375 shares of Puma common stock to three new non-executive employees.